EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Control of poorly immunogenic tumors with systemic STING agonist‐loaded liposomes targeting cross‐presenting dendritic cells

Bijun Zeng iD, Meghna Talekar iD, Thais Aragao-Horoiwa iD, Amy Cameron iD, Guangzu Zhao iD, Yulia Zybina, Wendy Blumenschein, Karyn van de Mark, Wittaya Suwakulsiri iD, Gretchen A Baltus, Riccardo Dolcetti iD, Ranjeny Thomas iD

Clinical & Translational Immunology · 2026-06 · 15 (6)

DOI: 10.1002/cti2.70110 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical & Translational Immunology, online erschienen am 01.06.2026. Verfasst von Bijun Zeng und 11 weiteren Autor:innen. Beteiligte Einrichtung: Frazer Institute The University of Queensland Brisbane QLD Australia. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: MSD Sharp and Dohme, National Health and Medical Research Council, Arthritis Queensland.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

Cancer vaccines combine tumor antigen and adjuvant to drive an anti‐tumor immune response. Clec9A‐targeted nanoparticles directing CD4 and CD8 neo‐epitopes to cross‐presenting dendritic cells (DCs) stimulate adjuvant‐free therapeutically effective tumor‐specific immunity. However, personalised neo‐epitopes limit the scalability of Clec9A nanoparticles for clinical translation. Since Clec9A + DCs constitutively present relevant neoepitopes in tumors but are suppressed in tumor microenvironments, we developed Clec9A‐targeted STING or RIG‐I liposomes to enhance endogenous tumor immunity.

Methods

Liposomes encapsulating RIG‐I or the STING agonist MSA‐1 and functionalised with Clec9A binding peptide WH were optimised for uptake by Clec9A + conventional and plasmacytoid DCs in vivo . Biodistribution after i.v. administration was determined with in vivo imaging and cellular uptake and activation with flow cytometry. Plasma was analysed for type 1 interferon (IFN) by ELISA and liver, spleen, tumor, blood, kidney, heart and tumor draining lymph node transcriptomes were analysed with Nanostring. Effects on tumor growth and survival, and tumor‐specific T cells were evaluated using the B16 melanoma model.

Results

Clec9A‐targeting liposomes administered i.v. were distributed to spleen, liver and tumor and were taken up by cross‐presenting and plasmacytoid DCs. Type 1 IFN production and DC, B‐ and T‐cell activation were more effective with i.v. Clec9A‐STING than Clec9A‐RIG‐I liposomes. Intravenous Clec9A‐STING liposomes stimulated IFN‐dependent transcription in blood, lung, tumor, and draining lymph nodes. Intravenous Clec9A‐STING liposomes, or intra‐tumoral Clec9A‐RIG‐I liposomes significantly suppressed B16‐F10 melanoma growth and induced neo‐epitope and survivin‐specific CD4 + and CD8 + T‐cell responses.

Conclusions

Clec9A‐STING liposomes are a scalable, translatable tumor‐targeted immunotherapy platform.

Schlagwörter

Stichwörter der Autor:innen

STINGcross presentationdendritic cellsliposomemelanoma

Autor:innen und Institutionen

  • Frazer Institute The University of Queensland Brisbane QLD Australia.
  • Present address: Peter MacCallum Cancer Centre and University of Melbourne Melbourne VIC Australia.
  • Present address: CSL Ltd Melbourne VIC Australia.
  • Present address: James Cook University Brisbane QLD Australia.
  • Merck & Co., Inc. Rahway NJ USA.

ORCID-Profile: Bijun Zeng, Meghna Talekar, Thais Aragao-Horoiwa, Amy Cameron, Guangzu Zhao, Wittaya Suwakulsiri, Riccardo Dolcetti, Ranjeny Thomas

Förderung

  • MSD Sharp and Dohme
  • National Health and Medical Research Council
  • Arthritis Queensland

Zitieren

APA

Zeng, B., Talekar, M., Aragao-Horoiwa, T., Cameron, A., Zhao, G., Zybina, Y., Blumenschein, W., van de Mark, K., Suwakulsiri, W., Baltus, G. A., Dolcetti, R., & Thomas, R. (2026). Control of poorly immunogenic tumors with systemic STING agonist‐loaded liposomes targeting cross‐presenting dendritic cells. Clinical & Translational Immunology, 15(6). https://doi.org/10.1002/cti2.70110

Vancouver

Zeng B, Talekar M, Aragao-Horoiwa T, Cameron A, Zhao G, Zybina Y, et al. Control of poorly immunogenic tumors with systemic STING agonist‐loaded liposomes targeting cross‐presenting dendritic cells. Clinical & Translational Immunology. 2026;15(6). doi:10.1002/cti2.70110

BibTeX
@article{Zeng2026,
  author = {Zeng, Bijun and Talekar, Meghna and Aragao-Horoiwa, Thais and Cameron, Amy and Zhao, Guangzu and Zybina, Yulia and Blumenschein, Wendy and van de Mark, Karyn and Suwakulsiri, Wittaya and Baltus, Gretchen A and Dolcetti, Riccardo and Thomas, Ranjeny},
  title = {Control of poorly immunogenic tumors with systemic STING agonist‐loaded liposomes targeting cross‐presenting dendritic cells},
  journal = {Clinical & Translational Immunology},
  year = {2026},
  volume = {15},
  number = {6},
  doi = {10.1002/cti2.70110}
}
Kostenlos starten →